Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Brian Druker, François Guilhot, Stephen G. O'Brien, Insa Gathmann, Hagop Kantarjian, Norbert Gattermann, Michael W N Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice L. Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy Hughes, Hermine Agis, Thomas Fischer & 12 others Gregor Verhoef, John Shepherd, Giuseppe Saglio, Alois Gratwohl, Johan L. Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson

Research output: Contribution to journalArticle

2527 Citations (Scopus)

Abstract

BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P

Original languageEnglish (US)
Pages (from-to)2408-2417
Number of pages10
JournalNew England Journal of Medicine
Volume355
Issue number23
DOIs
StatePublished - Dec 7 2006

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Leukemia, Myeloid, Accelerated Phase
Blast Crisis
Cytarabine
Interferon-alpha
Leukemia, Myeloid, Chronic Phase
Kaplan-Meier Estimate
Imatinib Mesylate
Protein-Tyrosine Kinases
Disease-Free Survival
Disease Progression
Phosphotransferases
Survival
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Druker, B., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., ... Larson, R. A. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23), 2408-2417. https://doi.org/10.1056/NEJMoa062867

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. / Druker, Brian; Guilhot, François; O'Brien, Stephen G.; Gathmann, Insa; Kantarjian, Hagop; Gattermann, Norbert; Deininger, Michael W N; Silver, Richard T.; Goldman, John M.; Stone, Richard M.; Cervantes, Francisco; Hochhaus, Andreas; Powell, Bayard L.; Gabrilove, Janice L.; Rousselot, Philippe; Reiffers, Josy; Cornelissen, Jan J.; Hughes, Timothy; Agis, Hermine; Fischer, Thomas; Verhoef, Gregor; Shepherd, John; Saglio, Giuseppe; Gratwohl, Alois; Nielsen, Johan L.; Radich, Jerald P.; Simonsson, Bengt; Taylor, Kerry; Baccarani, Michele; So, Charlene; Letvak, Laurie; Larson, Richard A.

In: New England Journal of Medicine, Vol. 355, No. 23, 07.12.2006, p. 2408-2417.

Research output: Contribution to journalArticle

Druker, B, Guilhot, F, O'Brien, SG, Gathmann, I, Kantarjian, H, Gattermann, N, Deininger, MWN, Silver, RT, Goldman, JM, Stone, RM, Cervantes, F, Hochhaus, A, Powell, BL, Gabrilove, JL, Rousselot, P, Reiffers, J, Cornelissen, JJ, Hughes, T, Agis, H, Fischer, T, Verhoef, G, Shepherd, J, Saglio, G, Gratwohl, A, Nielsen, JL, Radich, JP, Simonsson, B, Taylor, K, Baccarani, M, So, C, Letvak, L & Larson, RA 2006, 'Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia', New England Journal of Medicine, vol. 355, no. 23, pp. 2408-2417. https://doi.org/10.1056/NEJMoa062867
Druker B, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine. 2006 Dec 7;355(23):2408-2417. https://doi.org/10.1056/NEJMoa062867
Druker, Brian ; Guilhot, François ; O'Brien, Stephen G. ; Gathmann, Insa ; Kantarjian, Hagop ; Gattermann, Norbert ; Deininger, Michael W N ; Silver, Richard T. ; Goldman, John M. ; Stone, Richard M. ; Cervantes, Francisco ; Hochhaus, Andreas ; Powell, Bayard L. ; Gabrilove, Janice L. ; Rousselot, Philippe ; Reiffers, Josy ; Cornelissen, Jan J. ; Hughes, Timothy ; Agis, Hermine ; Fischer, Thomas ; Verhoef, Gregor ; Shepherd, John ; Saglio, Giuseppe ; Gratwohl, Alois ; Nielsen, Johan L. ; Radich, Jerald P. ; Simonsson, Bengt ; Taylor, Kerry ; Baccarani, Michele ; So, Charlene ; Letvak, Laurie ; Larson, Richard A. / Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. In: New England Journal of Medicine. 2006 ; Vol. 355, No. 23. pp. 2408-2417.
@article{c6510eff35074ff89b2782ad9884c6c8,
title = "Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia",
abstract = "BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69{\%} by 12 months and 87{\%} by 60 months. An estimated 7{\%} of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89{\%} at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P",
author = "Brian Druker and Fran{\cc}ois Guilhot and O'Brien, {Stephen G.} and Insa Gathmann and Hagop Kantarjian and Norbert Gattermann and Deininger, {Michael W N} and Silver, {Richard T.} and Goldman, {John M.} and Stone, {Richard M.} and Francisco Cervantes and Andreas Hochhaus and Powell, {Bayard L.} and Gabrilove, {Janice L.} and Philippe Rousselot and Josy Reiffers and Cornelissen, {Jan J.} and Timothy Hughes and Hermine Agis and Thomas Fischer and Gregor Verhoef and John Shepherd and Giuseppe Saglio and Alois Gratwohl and Nielsen, {Johan L.} and Radich, {Jerald P.} and Bengt Simonsson and Kerry Taylor and Michele Baccarani and Charlene So and Laurie Letvak and Larson, {Richard A.}",
year = "2006",
month = "12",
day = "7",
doi = "10.1056/NEJMoa062867",
language = "English (US)",
volume = "355",
pages = "2408--2417",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "23",

}

TY - JOUR

T1 - Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

AU - Druker, Brian

AU - Guilhot, François

AU - O'Brien, Stephen G.

AU - Gathmann, Insa

AU - Kantarjian, Hagop

AU - Gattermann, Norbert

AU - Deininger, Michael W N

AU - Silver, Richard T.

AU - Goldman, John M.

AU - Stone, Richard M.

AU - Cervantes, Francisco

AU - Hochhaus, Andreas

AU - Powell, Bayard L.

AU - Gabrilove, Janice L.

AU - Rousselot, Philippe

AU - Reiffers, Josy

AU - Cornelissen, Jan J.

AU - Hughes, Timothy

AU - Agis, Hermine

AU - Fischer, Thomas

AU - Verhoef, Gregor

AU - Shepherd, John

AU - Saglio, Giuseppe

AU - Gratwohl, Alois

AU - Nielsen, Johan L.

AU - Radich, Jerald P.

AU - Simonsson, Bengt

AU - Taylor, Kerry

AU - Baccarani, Michele

AU - So, Charlene

AU - Letvak, Laurie

AU - Larson, Richard A.

PY - 2006/12/7

Y1 - 2006/12/7

N2 - BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P

AB - BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P

UR - http://www.scopus.com/inward/record.url?scp=33845444046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845444046&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa062867

DO - 10.1056/NEJMoa062867

M3 - Article

VL - 355

SP - 2408

EP - 2417

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 23

ER -